

**Case-based implementation of  
immune checkpoint inhibitors in  
endometrial cancer through  
shared decision making**



# Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities*
- *touchIME accept no responsibility for errors or omissions*

# Expert MDT panel



**Prof. Christian Marth**  
**Gynaecological Oncologist**  
Medical University Innsbruck,  
Austria




**Dr Ilaria Colombo**  
**Medical Oncologist**  
Oncology Institute of Southern  
Switzerland, Bellinzona, Switzerland



**Dr Tjalling Bosse**  
**Pathologist**  
Leiden University Medical Center,  
Netherlands

# Diagnostic and prognostic algorithm for molecular endometrial cancer classification



2L, second line; EC, endometrial cancer; MMR, mismatch repair; MMRd, MMR deficient; mut, mutated; NOS, not otherwise specified; NSMP, non-specific molecular profile; p53, tumour protein p53; POLE, DNA polymerase epsilon.

1. Vermij L, et al. *Histopathology*. 2020;76:52–63; 2. Concin N, et al. *Int J Gynecol Cancer*. 2021;31:12–39.